1-Rabies
Provides protection against rabies in dogs, cats and ferrets for at least one year.
Product Description
NOBIVAC® 1-RABIES provides protection against Rabies
This product has been shown to be effective for the vaccination of healthy dogs, cats and ferrets 12 weeks of age or older against rabies. Duration of immunity of at least 1 year has been demonstrated after repeat dose. For more information regarding efficacy and safety data, go to productdata.aphis.usda.gov.
- Produced on an established cell line that has been extensively tested1
- A duration of immunity study demonstrated that a 1 mL dose met federal guidelines for protection of dogs, cats and ferrets against virulent challenge administered more than a year after vaccination1
Indications
Effective for the vaccination of healthy dogs, cats, and ferrets, 12 weeks of age or older against rabies.
EFFICACY & COMPARISONS
Rabies Challenge Studies
- Duration of immunity studies demonstrated that a 1 mL dose met federal guidelines for protection of dogs, cats and ferrets against virulent challenge administered 1 year after vaccination.
NOBIVAC® 1-RABIES IS A SAFE CHOICE
Proven to be uniformly safe in experimental tests, with no significant adverse reactions in extensive clinical trials.1
ADMINISTRATION AND DOSAGE
- Subcutaneous 1 mL injection for cats
- Subcutaneous 1 mL injection for ferrets
- Subcutaneous or intramuscular 1 mL injection for dogs
- Annual revaccination with 1 dose is recommended
- Available in a 5 x 10 mL presentation
ALSO AVAILABLE IN OTHER FORMULATIONS
DISEASE INFORMATION
Professional Resources and Educational Materials
Keep your clinic and staff informed and aware of diseases and outbreaks.
View More Nobivac ResourcesReferences
Go To United States
Algeria
Argentina
Australia
Austria
Bahrain
Belgium (Dutch)
Brazil
Canada (English)
Chile
Colombia
Croatia
Czech Republic
Denmark
Ecuador
Egypt
Finland
France
Germany
Greece
Hungary
India
Indonesia
Iraq
Ireland
Israel
Italy
Japan
Jordan
Kuwait
Lebanon
Malaysia
Mexico
Morocco
Netherlands
New Zealand
Norway
Oman
Panama
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russian Federation
Saudi Arabia
South Africa
South Korea
Spain
Sweden
Switzerland (French)
Taiwan
Thailand
Tunisia
Turkey
Ukraine
United Arab Emirates
United Kingdom
Uruguay
Yemen
Global